4/19
05:23 pm
asln
ASLAN Pharmaceuticals announces receipt of Nasdaq notice [Seeking Alpha]
Neutral
Report
ASLAN Pharmaceuticals announces receipt of Nasdaq notice [Seeking Alpha]
4/19
05:16 pm
asln
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice [Yahoo! Finance]
Neutral
Report
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice [Yahoo! Finance]
4/19
05:10 pm
asln
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
Neutral
Report
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
4/15
08:11 am
asln
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
4/12
08:14 am
asln
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
4/12
08:00 am
asln
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
High
Report
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4/9
11:02 am
asln
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? [Yahoo! Finance]
3/27
08:12 am
asln
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders [Yahoo! Finance]
Low
Report
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders [Yahoo! Finance]
3/27
08:07 am
asln
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
Low
Report
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
3/18
03:15 pm
asln
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $10.00 price target on the stock, down previously from $15.00.
Medium
Report
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $10.00 price target on the stock, down previously from $15.00.
3/18
02:52 pm
asln
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its price target lowered by analysts at HC Wainwright from $17.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its price target lowered by analysts at HC Wainwright from $17.00 to $9.00. They now have a "buy" rating on the stock.
3/12
02:58 pm
asln
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering [Yahoo! Finance]
High
Report
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering [Yahoo! Finance]
3/12
02:34 pm
asln
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
High
Report
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
3/11
07:35 am
asln
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients [Yahoo! Finance]
High
Report
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients [Yahoo! Finance]
3/11
07:00 am
asln
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
High
Report
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
3/6
07:12 am
asln
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors [Yahoo! Finance]
Low
Report
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors [Yahoo! Finance]
3/6
07:00 am
asln
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
High
Report
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
2/29
07:23 am
asln
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat [Yahoo! Finance]
High
Report
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat [Yahoo! Finance]
2/29
07:00 am
asln
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
High
Report
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat